Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm
{{output}}
Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantat... ...
